Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
"The degree of mean weight reduction seen in SURMOUNT-2 has not been previously achieved in phase 3 trials for obesity or overweight and type 2 diabetes." Participants taking tirzepatide achieved average weight reductions of 13.4% (29.8 lb.) on the lower dose of 10 mg and 15.7% (34.4 lb.) on the higher dose of 15 mg, compared to a placebo group
Eat within a consistent daily window (like 8am-7pm) rather than grazing all day, as this improves hormonal signaling
Eagerly jumping to higher doses can expose you to severe nausea and other unwanted side effects
Have a product question
Nearly 9 million Americans now use GLP-1 receptor agonist therapy for weight management, and the majority learn to self-inject at home
Type 2 diabetes with chronic kidney disease or elevated inflammatory burden
US$ 28.73
US$ 26.45
US$ 28.49
US$ 21.57
US$ 20.36
US$ 22.56
US$ 20.02
US$ 27.31
US$ 29.34
